Lexeo Therapeutics Statistics
 Total Valuation
 LXEO has a market cap or net worth of $629.39 million. The enterprise value is $504.01 million.
   Important Dates
 The next estimated earnings date is Friday, November 14, 2025, before market open.
 | Earnings Date  | Nov 14, 2025 | 
| Ex-Dividend Date  | n/a | 
  Share Statistics
 LXEO has 69.62 million shares outstanding. The number of shares has increased by 80.52% in one year.
 | Current Share Class  | 69.62M | 
| Shares Outstanding  | 69.62M | 
| Shares Change (YoY)  | +80.52% | 
| Shares Change (QoQ)  | +31.59% | 
| Owned by Insiders (%)  | 0.29% | 
| Owned by Institutions (%)  | 47.40% | 
| Float  | 48.79M | 
   Valuation Ratios
  | PE Ratio  | n/a | 
| Forward PE  | n/a | 
| PS Ratio  | n/a | 
| Forward PS  | n/a | 
| PB Ratio  | 3.91 | 
| P/TBV Ratio  | 4.54 | 
| P/FCF Ratio  | n/a | 
| P/OCF Ratio  | n/a | 
| PEG Ratio  | n/a | 
 Financial Ratio History  Enterprise Valuation
  | EV / Earnings  | n/a | 
| EV / Sales  | n/a | 
| EV / EBITDA  | n/a | 
| EV / EBIT  | n/a | 
| EV / FCF  | n/a | 
  Financial Position
 The company has a current ratio of 4.43, with a Debt / Equity ratio of 0.06.
 | Current Ratio  | 4.43 | 
| Quick Ratio  | 4.21 | 
| Debt / Equity  | 0.06 | 
| Debt / EBITDA  | n/a | 
| Debt / FCF  | n/a | 
| Interest Coverage  | -1,045.92 | 
   Financial Efficiency
 Return on equity (ROE) is -75.32% and return on invested capital (ROIC) is -47.77%.
 | Return on Equity (ROE)  | -75.32% | 
| Return on Assets (ROA)  | -41.91% | 
| Return on Invested Capital (ROIC)  | -47.77% | 
| Return on Capital Employed (ROCE)  | -85.43% | 
| Revenue Per Employee  | n/a | 
| Profits Per Employee  | -$1.59M | 
| Employee Count | 72 | 
| Asset Turnover  | n/a | 
| Inventory Turnover  | n/a | 
  Taxes
  | Income Tax  | n/a | 
| Effective Tax Rate  | n/a | 
  Stock Price Statistics
 The stock price has increased by +12.67% in the last 52 weeks.
 | Beta (5Y)  | n/a | 
| 52-Week Price Change  | +12.67% | 
| 50-Day Moving Average  | 6.95 | 
| 200-Day Moving Average  | 4.61 | 
| Relative Strength Index (RSI)  | 54.64 | 
| Average Volume (20 Days)  | 1,693,714 | 
  Short Selling Information
 The latest short interest is 7.32 million, so 10.51% of the outstanding shares have been sold short.
 | Short Interest  | 7.32M | 
| Short Previous Month  | 5.96M | 
| Short % of Shares Out  | 10.51% | 
| Short % of Float  | 14.99% | 
| Short Ratio (days to cover)  | 5.80 | 
  Income Statement
  | Revenue  | n/a | 
| Gross Profit  | -73.68M | 
| Operating Income  | -123.42M | 
| Pretax Income  | -114.17M | 
| Net Income  | -114.17M | 
| EBITDA  | -122.82M | 
| EBIT  | -123.42M | 
| Earnings Per Share (EPS)  | -$3.20 | 
 Full Income Statement  Balance Sheet
 The company has $132.89 million in cash and $8.91 million in debt, giving a net cash position of $123.98 million or $1.78 per share.
 | Cash & Cash Equivalents  | 132.89M | 
| Total Debt  | 8.91M | 
| Net Cash  | 123.98M | 
| Net Cash Per Share  | $1.78 | 
| Equity (Book Value)  | 138.22M | 
| Book Value Per Share  | 2.56 | 
| Working Capital  | 108.47M | 
 Full Balance Sheet  Cash Flow
 In the last 12 months, operating cash flow was -$95.07 million and capital expenditures -$191,000, giving a free cash flow of -$95.26 million.
 | Operating Cash Flow  | -95.07M | 
| Capital Expenditures  | -191,000 | 
| Free Cash Flow  | -95.26M | 
| FCF Per Share  | -$1.37 | 
 Full Cash Flow Statement  Margins
  | Gross Margin  | n/a | 
| Operating Margin  | n/a | 
| Pretax Margin  | n/a | 
| Profit Margin  | n/a | 
| EBITDA Margin  | n/a | 
| EBIT Margin  | n/a | 
| FCF Margin  | n/a | 
  Dividends & Yields
 LXEO does not appear to pay any dividends at this time.
 | Dividend Per Share  | n/a | 
| Dividend Yield  | n/a | 
| Dividend Growth (YoY)  | n/a | 
| Years of Dividend Growth  | n/a | 
| Payout Ratio  | n/a | 
| Buyback Yield  | -80.52% | 
| Shareholder Yield  | -80.52% | 
| Earnings Yield  | -18.18% | 
| FCF Yield  | -15.17% | 
    Analyst Forecast
 The average price target for LXEO is $18.13, which is 100.55% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target  | $18.13 | 
| Price Target Difference  | 100.55% | 
| Analyst Consensus  | Strong Buy | 
| Analyst Count  | 8 | 
| Revenue Growth Forecast (5Y)  | n/a | 
| EPS Growth Forecast (5Y)  | -49.98% | 
 Stock Forecasts  Fair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value  | n/a | 
| Lynch Upside  | n/a | 
| Graham Number  | n/a | 
| Graham Upside  | n/a | 
  Stock Splits
 This stock does not have any record of stock splits.
 | Last Split Date  | n/a | 
| Split Type  | n/a | 
| Split Ratio  | n/a | 
  Scores
  | Altman Z-Score  | n/a | 
| Piotroski F-Score  | 1 |